In Utero Exposure to Flame Retardants Tied to Worse Birth Outcomes
By Lori Solomon HealthDay Reporter
MONDAY, Feb. 5, 2024 -- Gestational exposures to several organophosphate esters (OPEs) are associated with earlier timing of birth, especially among female neonates, or with greater fetal growth, according to a study published online Jan. 24 in Environmental Health Perspectives.
Jiwon Oh, Ph.D., from the University of California Davis, and colleagues assessed associations between gestational OPE exposures and adverse birth outcomes. The analysis included data from 6,646 pregnant participants from 16 cohorts in the Environmental Influences on Child Health Outcomes Program.
The researchers found that three OPE biomarkers (diphenyl phosphate [DPHP], a composite of dibutyl phosphate and di-isobutyl phosphate [DBUP/DIBP], and bis [1,3-dichloro-2-propyl] phosphate) were detected in >85 percent of participants. DBUP/DIBP (odds ratio [OR] per doubling, 1.07) and bis(butoxyethyl) phosphate (odds ratio for high versus nondetect, 1.25) were associated with higher odds of preterm birth, but other OPE biomarkers were not. The adverse effect for associations of DPHP and high bis(2-chloroethyl) phosphate with completed gestational weeks and odds of preterm birth were seen among females. Newborns of mothers with detectable bis(1-chloro-2-propyl) phosphate, bis(2-methylphenyl) phosphate, and dipropyl phosphate had higher birth weight-for-gestational-age z scores (β for detect versus nondetect, 0.04 to 0.07).
"Our findings guide our understanding of how these chemicals may be silently seeding lasting challenges for the health of the next generation," Oh said in a statement.
Several authors reported consulting for relevant organizations.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
ADA: Bisphenol A Linked to Reduced Peripheral Insulin Sensitivity
THURSDAY, June 27, 2024 -- Bisphenol A (BPA) administration is associated with reduced peripheral insulin sensitivity among healthy adults, according to a study presented at the...
COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes
TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...
NT-proBNP, IL-1RL Can Identify High-Risk Congenital Heart Disease in Neonates
MONDAY, June 24, 2024 -- Automated quantitative tests for NT-proBNP and interleukin 1 receptor-like 1 (IL-1 RL1) can identify high-risk congenital heart disease (CHD) in newborns...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.